Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent

NCT04844749 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

105

Enrollment

INDUSTRY

Sponsor class

Stopped Administrative reasons

Conditions

Metastatic Castration-resistant Prostate Cancer
Androgen Resistant Prostatic Cancer

Interventions

DRUG: VERU-111
DRUG: Enzalutamide, Abiraterone

Sponsor

Veru Inc.